Why do rare disease trials need specialist CROs?

Rare disease trials face unique challenges: very small patient populations, geographically dispersed sites, novel endpoints, and complex regulatory pathways including orphan drug designation. Specialist CROs have established rare disease networks and expertise in natural history studies.

What regulatory considerations apply to orphan drug trials?

Orphan drug trials may benefit from incentives like market exclusivity, tax credits, and fee waivers. They often require adaptive designs, seamless phases, and engagement with regulators early via pre-IND meetings and scientific advice.

How many rare disease CROs are on Clinical Vendor Compare?

Clinical Vendor Compare profiles 650+ clinical trial vendors across 17 categories, including specialist CROs with rare disease and orphan drug expertise. Filter by category and therapeutic area to find the right partner.

Best CROs for Rare Disease & Orphan Drug Clinical Trials

Rare disease trials are fundamentally different from standard drug development. With patient populations sometimes numbering in the hundreds worldwide, sponsors need CROs with established rare disease networks, adaptive trial design expertise, and deep regulatory knowledge of orphan drug pathways.

Key Challenges in Rare Disease Trials

Small patient populations � Often fewer than 200 patients globally, requiring multinational site networks
Geographic dispersion � Patients and investigators spread across many countries and continents
Novel endpoints � Biomarker-driven or composite endpoints unique to each rare condition
Natural history studies � Often required as a baseline comparator when placebo arms are unethical
Regulatory incentives � Orphan drug designation, priority review vouchers, and accelerated assessment pathways

Selecting a Rare Disease CRO

When evaluating CROs for rare disease programmes, consider:

Track record in specific rare disease therapeutic areas
Established relationships with patient advocacy groups and rare disease registries
Experience with adaptive and Bayesian trial designs suitable for small samples
Global reach with capability to activate sites in underrepresented regions
Regulatory strategy experience with EMA, FDA, and PMDA orphan drug applications

Compare Rare Disease CROs

Browse Clinical Vendor Compare's independent directory of 650+ vendors. Filter by specialist CRO category, therapeutic expertise, and geography to find the right partner for your rare disease programme.

Browse All Vendors